Translate this page into:
Tektrotyd Scan Showing a Diffuse Bone Metastasis in Patient with a Neuroendocrine Pancreatic Tumor
Address for correspondence: Dr. Ali Sellem, Department of Nuclear Medicine, Military Hospital of Tunis, Tunis, Tunisia. E-mail: sellem_ali@yahoo.fr
-
Received: ,
Accepted: ,
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
This article was originally published by Wolters Kluwer - Medknow and was migrated to Scientific Scholar after the change of Publisher.
Abstract
A 65-year-old woman presented with a neuroendocrine pancreatic head tumor and known liver and bone metastasis. We performed Tc-99m-tektrotyd scintigraphy on this patient, which showed more developed diffuse bone metastases, in addition to the known lesions.
Keywords
Bone marrow metastasis
neuroendocrine tumor
pancreatic tumor
somatostatinreceptor scintigraphy
A 65-year-old woman with pancreatic neuroendocrine tumor (NET) who has hepatic and skeletal metastases discovered with contrast-enhanced computed tomography. The patient underwent two full-body scans acquired 15 min and 3 h after intravenous injection of 740 MBq (20 mCi) of 99mTc-ethylenediammonium diacetate- tricine-hydrazinonicotinamide-Tyr0- octreotide (Tektrotyd) which showing an intense uptake in the area of the head pancreatic mass, in the liver metastasis [Figure 1] and in diffuse bone metastasis interesting the axial and peripheral skeleton [Figure 2].
Pancreatic NETs are rare neoplasms that develop from the endocrine tissues of the pancreas. The reported incidence of 0.0003% to 0.001% of all cancers.[123] This incidence has been increasing throughout the world over the past two decades.[34] About 32%–73% of cases are metastatic at the moment of diagnosis.[45] The most common site of metastatic disease involvement for pancreatic NET is the liver.[678] Only 6%–13% of pancreatic NET patients will demonstrate skeletal metastasis.[910] Diffuse bone metastases in the entire axial and appendicular skeleton, as the case of our patient, are rare.[91011121314] The European NET Society consensus guidelines recommend the use of both anatomic imaging, i.e. magnetic resonance imaging and functional whole-body imaging methods, including bone scintigraphy and somatostatin receptor scintigraphy (SRS), for the detection of bone metastases.[15] In the last few decades, the superior value of positron emission tomography/computed tomography (PET/CT) over SRS in the diagnosis of NENs, particularly after the introduction of 68Ga-DOTA-peptides that specifically bind to somatostatin receptors, has been widely demonstrated.[16] In our department, we do not have PET/CT that is why we use tektrotyd.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
References
- Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727-33.
- [Google Scholar]
- One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-72.
- [Google Scholar]
- Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121:589-97.
- [Google Scholar]
- Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335-42.
- [Google Scholar]
- Clinicopathological features of pancreatic endocrine tumors: A prospective multicenter study in Italy of 297 sporadic cases. Am J Gastroenterol. 2010;105:1421-9.
- [Google Scholar]
- Treatment of liver metastases in patients with neuroendocrine tumors: A comprehensive review. Int J Hepatol. 2011;2011:154541.
- [Google Scholar]
- The epidemiology of metastases in neuroendocrine tumors. Int J Cancer. 2016;139:2679-86.
- [Google Scholar]
- Bone metastases in carcinoid tumors: Clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med. 2003;44:184-91.
- [Google Scholar]
- Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr Connect. 2015;4:9-17.
- [Google Scholar]
- Endocrine pancreatic tumors: Factors correlated with survival. Ann Oncol. 2005;16:1806-10.
- [Google Scholar]
- Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: Comparison with OctreoScan ® in two cases. World J Surg Oncol. 2012;10:82.
- [Google Scholar]
- Metastatic neuroendocrine tumor with extensive bone marrow involvement at diagnosis: Evaluation of response and hematological toxicity profile of PRRT with (177) Lu-DOTATATE. World J Nucl Med. 2016;15:38-43.
- [Google Scholar]
- Diffuse bone metastases in pancreatic neuroendocrine tumor shown on octreoscan. Clin Nucl Med. 2019;44:257-8.
- [Google Scholar]
- ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. Neuroendocrinology. 2010;91:341-50.
- [Google Scholar]
- 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: A prospective trial. J Nucl Med. 2014;55:1598-604.
- [Google Scholar]